CALCA and migraine disorder: Although current migraine treatments which target CGRP and the canonical CGRP receptor provide relief for many migraine patients, there are patients who do not respond, suggesting that there is scope to develop further treatments (Edvinsson et al., 2018; Dubowchik et al., 2020).